PT-141 Bulk Supplier — Argentina
Research Use Only: All compounds supplied by Aarise Healthcare are strictly for laboratory research and scientific investigation. Not intended for human consumption, therapeutic use, or clinical application. All purchases must comply with applicable local laws and regulations.
Aarise Healthcare exports PT-141 (CAS: 189691-06-3) to research institutions in Argentina. Our WHO-GMP certified facility in India supplies 98%+ purity PT-141 for melanocortin receptor and sexual function research.
PT-141 Export Specifications for Argentina
| Compound | PT-141 |
| CAS Number | 189691-06-3 |
| Purity | 98%+ (HPLC verified) |
| Form | Lyophilised powder |
| Regulatory Reference | ANMAT |
| Shipping | DHL/FedEx temperature-controlled |
| Transit to Argentina | 5-10 business days |
| Documentation | CoA, HPLC, MS, export docs |
Research Applications of PT-141
PT-141 is used in melanocortin receptor and sexual function research. Research institutions in Argentina source this compound for preclinical studies under applicable ANMAT research regulations.
Why Argentina Researchers Source PT-141 from India
- WHO-GMP certified Indian manufacturer — internationally recognised compliance
- Competitive pricing for bulk research quantities
- Full export documentation package for ANMAT compliance
- Temperature-controlled DHL/FedEx shipping to Argentina
- Dedicated international research supply team
- 98%+ purity guaranteed with independent third-party CoA
Related Peptides in Argentina
Semaglutide in Argentina | Tirzepatide in Argentina | Retatrutide in Argentina | Liraglutide in Argentina
PT-141 — Other Countries
PT-141 in USA | PT-141 in UK | PT-141 in Germany | PT-141 in Australia
Source from India — Key Manufacturing Cities
PT-141 in Mumbai, India | PT-141 in Delhi, India | PT-141 in Hyderabad, India | PT-141 in Bangalore, India
Request PT-141 for your Argentina research facility: Send your institution details and quantity requirements. We respond within 24 hours with FOB pricing and export documentation.
